188 related articles for article (PubMed ID: 22298660)
1. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
[TBL] [Abstract][Full Text] [Related]
2. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
[TBL] [Abstract][Full Text] [Related]
3. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
[TBL] [Abstract][Full Text] [Related]
4. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
Figueiredo Junior AG; Forones NM
Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
6. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
Twelves C; Gollins S; Grieve R; Samuel L
Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
[TBL] [Abstract][Full Text] [Related]
7. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
[TBL] [Abstract][Full Text] [Related]
8. Oral capecitabine (Xeloda) in cancer treatment.
Doyle DP; Engelking C
Nurse Pract; 2007 Feb; 32(2):18-21. PubMed ID: 17264789
[No Abstract] [Full Text] [Related]
9. On prejudice and facts and choices.
Köhne CH; Folprecht G
Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
[No Abstract] [Full Text] [Related]
10. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
12. Over compliance with capecitabine oral chemotherapy.
Allen J; Williamson S
Int J Clin Pharm; 2014 Apr; 36(2):271-3. PubMed ID: 24532364
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
[TBL] [Abstract][Full Text] [Related]
14. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
Faithfull S; Deery P
Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
[TBL] [Abstract][Full Text] [Related]
15. [Oral capecitabine therapy: experience and developments at the Milano Cancer Institute].
Longo F; Mansueto G
Tumori; 2004; 90(1):suppl 17-27. PubMed ID: 15143996
[No Abstract] [Full Text] [Related]
16. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
Longo F; Mansueto G
Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
[No Abstract] [Full Text] [Related]
17. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
Saif MW
Clin Colorectal Cancer; 2005 Jul; 5(2):89-100. PubMed ID: 16098249
[TBL] [Abstract][Full Text] [Related]
19. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine: an overview of the side effects and their management.
Saif MW; Katirtzoglou NA; Syrigos KN
Anticancer Drugs; 2008 Jun; 19(5):447-64. PubMed ID: 18418212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
